Cyclopharm Limited (AU:CYC)
ASX:CYC
Want to see AU:CYC full AI Analyst Report?
CYC Stock Chart & Stats
AU$0.98
-AU$0.04(-1.82%)
At close: 4:00 PM EST
AU$0.98
-AU$0.04(-1.82%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$1.48
Previous CloseN/A
Volume20.15K
Average Volume (3M)97.64K
Market Cap
AU$91.40M
Enterprise ValueAU$101.58M
Total Cash (Recent Filing)AU$6.63M
Total Debt (Recent Filing)AU$14.92M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,065,790
10 Day Avg. Volume155,345
30 Day Avg. Volume97,642
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)3.98
Price to Sales (P/S)3.34
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside2.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$47.80M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSteady top-line growth through 2025 reflects improving commercial traction and expanding procedure volumes for Technegas. Durable revenue expansion supports scaling of the installed base and recurring consumable sales, providing a foundation for eventual margin recovery if costs or pricing are addressed.
Meaningful Equity BufferA ~27.1m equity base provides a material cushion to absorb ongoing operating losses and reduce short-term insolvency risk. This financial headroom helps preserve operating continuity, supports negotiation of financing or partnership terms, and increases time to execute any structural turnaround.
Recurring Consumable Revenue ModelTechnegas's consumable-led model creates repeatable, usage-driven revenue tied to installed systems and procedure volumes. High customer stickiness in hospital supplies and predictable per-procedure demand can produce steady cash inflows over time as installed base and utilization grow, supporting long-term revenue durability.
Bears Say
Negative Gross Profit In 2025A negative gross profit in 2025 indicates that product and direct costs exceeded revenue, signaling broken unit economics. This structural margin weakness undermines scalability: without durable cost reductions, pricing changes, or reimbursement improvements, revenue growth will not translate into sustainable profitability.
Large Operating Cash BurnPersistent and sizable negative operating and free cash flow (~-17.3m OCF, -19.3m FCF) creates ongoing funding needs. Over several months this forces reliance on external financing or asset sales, limits investment in commercialization or cost restructuring, and elevates dilution or refinancing risk absent rapid margin improvement.
Rising LeverageMaterial debt growth alongside declining equity raises leverage and financial risk. Higher interest and principal obligations reduce operational flexibility, increase sensitivity to cash-flow variability, and may restrict strategic options such as capex or M&A until profitability and cash generation are restored.
Cyclopharm Limited News
CYC FAQ
What was Cyclopharm Limited’s price range in the past 12 months?
Cyclopharm Limited lowest share price was AU$0.56 and its highest was AU$1.48 in the past 12 months.
What is Cyclopharm Limited’s market cap?
Cyclopharm Limited’s market cap is AU$91.40M.
When is Cyclopharm Limited’s upcoming earnings report date?
Cyclopharm Limited’s upcoming earnings report date is Sep 01, 2026 which is in 123 days.
How were Cyclopharm Limited’s earnings last quarter?
Cyclopharm Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.086.
Is Cyclopharm Limited overvalued?
According to Wall Street analysts Cyclopharm Limited’s price is currently Undervalued.
Does Cyclopharm Limited pay dividends?
Cyclopharm Limited pays a Semiannually dividend of AU$0.008 which represents an annual dividend yield of N/A. See more information on Cyclopharm Limited dividends here
What is Cyclopharm Limited’s EPS estimate?
Cyclopharm Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclopharm Limited have?
Cyclopharm Limited has 126,065,790 shares outstanding.
What happened to Cyclopharm Limited’s price movement after its last earnings report?
Cyclopharm Limited reported an EPS of -AU$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.765%.
Which hedge fund is a major shareholder of Cyclopharm Limited?
Currently, no hedge funds are holding shares in AU:CYC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cyclopharm Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (2.04% Upside)
AU$1.00 (2.04% Upside)
Blogger Sentiment
Bullish
AU:CYC Sentiment 87%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$75.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.35%
12-Months-Change
Fundamentals
Return on Equity
-54.48%
Trailing 12-Months
Asset Growth
-25.80%
Trailing 12-Months
Company Description
Cyclopharm Limited
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.
CYC Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(2.04% Upside)
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Aroa Biosurgery Ltd
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Options Prices
Currently, No data available
---